Quintrio
Home

SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC

Concentra Group Holdings Parent, Inc.

CON

Concentra Group Holdings Parent Inc is a provider of occupational health services in the USA. The business is organized into three operating segments: occupational health centers, onsite health clinics, and other businesses.

Last trade $42.64
Day change -$0.80 (-1.84%)
Day range $42.49 – $44.11
Volume 211,194
Market cap $5.46B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$5.46B
Price / earnings
25.06×
Price / book
10.77×
Price / sales
2.34×
EV / sales
2.95×
EV / EBITDA
14.5×

Profitability

Earnings per share
$1.73
Return on assets
7.24%
Return on equity
42.98%
Dividend yield
0.59%

Liquidity and leverage

Debt / equity
3×
Current ratio
1.3×
Quick ratio
1.3×
Cash ratio
0.24×

Cash flow

Price / cash flow
16.71×
Price / free cash flow
21.22×
Free cash flow
$257.4M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CON, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$622.12M$606.03M$569.56M$539.08M$572.8M$550.79M$500.75M$465.04M
Cost of revenue$426.65M$413.93M$399.09M$398.35M$405.54M$389.33M$357.1M$344.85M
Gross profit$195.47M$192.1M$170.47M$140.73M$167.27M$161.45M$143.65M$120.19M
Selling, general and administrative$60.93M$56.68M$55.28M$50.78M$52.88M$52.93M$46.71M$45.49M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$80.27M$77.03M$74.86M$71.07M$72.79M$71.91M$63.33M$61.1M
Operating income$115.2M$115.07M$95.61M$69.66M$94.47M$89.54M$80.32M$59.09M
Interest expense-$25.16M-$25.72M-$26M-$109.29M-$28.68M-$28.19M-$25.55M-$47.71M
Income before taxes$90.04M$89.35M$69.61M$42.79M$65.79M$61.35M$53.9M$32.65M
Income taxes$22.27M$22.05M$17.32M$6.6M$15.97M$15.16M$13.25M$9.85M
Net income$67.77M$67.3M$52.29M$36.19M$49.82M$46.19M$40.64M$22.8M
Net income attributable to common shareholders$65.89M$65.3M$50.49M$36.24M$48.26M$44.56M$38.91M$21.51M
EBITDA$135.35M$134.97M$115.26M$89.95M$114.38M$108.54M$96.94M$74.7M
Basic earnings per share$0.52$0.51$0.39$0.29$0.38$0.35$0.30$0.17
Diluted earnings per share$0.52$0.51$0.39$0.28$0.38$0.35$0.30$0.17

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

MDT Q2 Earnings Preview: Will Cardiovascular Performance Lift Results?

Medtronic is expected to report Q2 fiscal 2027 results on November 24, with revenues projected to grow 5.7% to $9.47 billion and EPS estimated at $1.34 (down 1.5% YoY). The Cardiovascular segment is expected to drive growth at 9.6%, supported by cardiac ablation, CRM, and structural heart products. Diabetes revenues are projected to grow 12.9% following the MiniMed separation. However, the company has a negative Earnings ESP of -0.75%, suggesting limited upside surprise potential.

Zacks Investment Research

Concentra Group (CON) Is Up 4.56% in One Week: What You Should Know

Concentra Group (CON) has earned a Momentum Style Score of A and a Zacks Rank #2 (Buy) rating, driven by strong short-term and long-term price performance that significantly outpaces its industry and the broader market. The stock has gained 4.56% over the past week, 12.95% monthly, 19.34% quarterly, and 120.14% annually, while recent earnings estimate revisions have moved upward with no downward adjustments in the past two months.

Zacks Investment Research

Take the Zacks Approach to Beat the Markets: Ulta Beauty, Accenture, HCA in Focus

Stock markets declined for the week ended November 6, with the Nasdaq, S&P 500, and Dow falling 3.4%, 2.7%, and 0.9% respectively, as investors reassessed AI valuations and infrastructure spending. A partial recovery on Friday was driven by stronger-than-expected October employment data, though concerns about potential Fed rate hikes persisted. Zacks highlighted several outperforming stocks across its various portfolios, including HCA Healthcare and Ulta Beauty from its Focus List, Accenture from its ECAP portfolio, and dividend stocks like Procter & Gamble and Automatic Data Processing.

Zacks Investment Research

Concentra Group (CON) Tops Q3 Earnings and Revenue Estimates

Concentra Group (CON) reported quarterly earnings of $0.52 per share, beating consensus estimates of $0.45 and surpassing revenue expectations with $622.12 million. The company has outperformed the market by 121.3% year-to-date and received a Zacks Rank #2 (Buy) rating. Canopy Growth Corporation (CGC) is expected to report a quarterly loss of $0.02 per share with revenues projected at $59.12 million.

Zacks Investment Research

CON vs. MEDP: Which Stock Is the Better Value Option?

A comparison of two Medical Services sector stocks, Concentra Group (CON) and Medpace (MEDP), both holding a Zacks Rank #2 (Buy). Based on valuation metrics including forward P/E ratios (24.46 vs 36.10), PEG ratios (1.47 vs 2.53), and P/B ratios (10.66 vs 31.18), Concentra Group is identified as the superior value opportunity with a Value grade of B compared to Medpace's C grade.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.0625 per share
Declared
Nov 4, 2026
Ex-dividend
Nov 19, 2026
Pay date
Dec 4, 2026
Ex-dividendAmount / sharePay dateType
Aug 20, 2026$0.0625Aug 28, 2026recurring
May 19, 2026$0.0625Jun 9, 2026recurring
Mar 12, 2026$0.0625Mar 19, 2026recurring
Dec 2, 2025$0.0625Dec 9, 2025recurring
Aug 21, 2025$0.0625Aug 28, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.